DiaMedica Therapeutics announced that the FDA has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke and that preparations are underway to resume the ReMEDy2 trial as soon as possible.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DMAC:
